Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function
Conditions: Heart Failure and Impaired Kidney Function Interventions: Drug: balcinrenone/dapagliflozin 15 mg/10 mg and matching placebo for dapagliflozin 10 mg; Drug: balcinrenone/dapagliflozin 40 mg/10 mg and matching placebo for dapagliflozin 10 mg; Drug: dapagliflozin 10 mg and matching placebo for balcinrenone/dapa gliflozin Sponsors: AstraZeneca Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: AstraZeneca | Cardiology | Dapagliflozin | Forxiga | Heart | Heart Failure | Research | Study | Urology & Nephrology